TG Therapeutics (TGTX +0.2%) announces the addition of ublituximab to ibrutinib significantly improves ORR compared to ibrutinib monotherapy (93% compared to 78%)
Complete response/complete response with
incomplete blood count recovery rate was (20% vs. 5%), and increased
rates of uMRD (46% vs. 7%)
At a median follow-up of 41.9 months, median PFS
was not reached in ublituximab + ibrutinib arm, and was 35.9 months in
the ibrutinib monotherapy arm
The combination did not significantly alter the
known safety profile of ibrutinib; slightly higher rates of neutropenia
and atrial fibrillation were observed with the combination
The trial includes data from 117 patients treated with either ublituximab + ibrutinib (n=59) or ibrutinib alone (n=58).
https://seekingalpha.com/news/3578671-tg-therapeutics-reports-phase-3-results-of-ublituximab-ibrutinib-combination-in-cll-patients
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.